Pennant Group Q2 2026: EPS Rises, Revenue Expands, and the Sector Keeps Its Pace

In this quarter, Pennant Group, Inc. (NASDAQ: PNTG) delivers a cohesive growth story: GAAP EPS of $0.25 and an adjusted EPS of $0.36 for Q2 2026, with revenue creeping toward the $300 million mark. The release provides EPS and EBITDA-style metrics that hint at operating leverage, but it leaves investors looking for a formal EPS consensus or explicit revenue forecast—a gap that often looms over a strong top-line quarter until guidance lands. Still, the quarter’s numbers portend a disciplined expansion in the Pennant ecosystem of home health, hospice, and senior living services.

Executive Snapshot

Ticker: PNTG (NASDAQ)
GAAP EPS: $0.25; Adjusted EPS: $0.36
Revenue: $298.0 million; +35.8% year over year
Net income: $9.1 million; +28.2% YoY
Consolidated Adjusted EBITDA: $24.3 million; +48.2% YoY
Consolidated Adjusted EBITDAR: $37.6 million; +33.3% YoY
Conference call: August 6, 2026, 10:00 a.m. MT (Eagle, Idaho)

No explicit EPS consensus or formal revenue forecast is presented in the release. In other words, the earnings surprise vector is not pre-baked into a single street expectation; investors will be left to parse the box score and guidance as it lands in future communications.

Quarter in Numbers

The top line was driven by robust demand across Pennant’s core segments. Revenue for the quarter totaled $298.0 million, up $78.5 million from the prior-year period, representing a 35.8% increase.

Net income reached $9.1 million, up $2.0 million or 28.2% versus the prior year quarter. Adjusted net income rose to $12.8 million, up $3.4 million or 36.5%.

From an EBITDA perspective, Consolidated Adjusted EBITDA was $24.3 million, up $7.9 million or 48.2% year over year. Consolidated Adjusted EBITDAR climbed to $37.6 million, up $9.4 million or 33.3%.

Additionally, Adjusted EBITDA prior to NCI stood at $26.1 million, up $8.8 million or 51.0% from the prior-year quarter.

Segment Spotlight: Home Health, Hospice, and Senior Living

The Home Health and Hospice Services segment posted revenue of $237.8 million for the quarter, up $71.8 million or 43.2% versus the prior year quarter. Within that, total home health admissions were 28,947 for Q2, with same-store admissions at 17,854—an increase of 1,573, or 9.7%, over the prior year quarter. Medicare home health admissions for the quarter were 11,916, up 4,936 or 70.7%.

Hospice metrics showed positive momentum as well, with hospice average daily census for the quarter at 5,477 and same-store census at 4,089, marking a meaningful rise over the prior year quarter.

Senior Living Services contributed $60.2 million in revenue for the quarter, up $6.7 million or 12.6% from the prior year quarter. The occupancy picture looks constructive, with average occupancy for the quarter at 78.9%.

Outlook and Sector Implications

What stands out is the breadth of growth across Pennant’s platform, rather than a single-number beat. The earnings story is supported by a strong top line and broadened EBITDA leverage, suggesting the company is scaling its operating model across home health, hospice, and senior living services. The absence of a formal revenue forecast or explicit EPS consensus in the release means investors will need to listen for cadence and guidance that clarifies how much of Q2’s strength is structural versus cyclical.

For peers in the space, Pennant’s trajectory underscores the importance of patient volumes, occupancy, and payer-mriendliness in extracting margin expansion. As the sector contends with wage pressures, reimbursement dynamics, and regulatory scrutiny, a quarter that blends robust admissions with rising occupancy and EBITDA growth could signal a template for sustainable expansion if the growth remains durable into the second half of the year.

What to Watch Next

The August 6, 2026 conference call will be the stage where Pennant clarifies its medium-term targets and capital allocation priorities. With no explicit street consensus laid out in the press release, the stock may trade on the plausibility of sustained margin expansion and the durability of the admissions trends observed in Q2.

Bottom Line: A Growth Narrative That Demands Follow-Through

In an environment where clinical and regulatory headwinds compete with patient demand, Pennant’s Q2 2026 results present a coherent growth narrative. The company expands revenue and improves margins, translating into higher EPS figures and stronger EBITDA metrics. If the cadence continues, investors might price the name as a growing platform of services with leverage on service mix and occupancy. And if you’re hunting for a lighter note, you could say the quarter delivered a tidy stack of numbers—the kind of stack that would impress even the most stubborn auditor, provided the bed count continues to rise as planned.